Known Medicine

Known Medicine addresses the fundamental problem that most cancer drugs fail in human trials despite showing promise in labs. ​​‌‌‌‌‌‌‌​‌‌​​‌​​​​​​‌‌​‌‌‌​​​‌‌Oncologists and their patients experienced this acutely—patients received chemotherapy or targeted drugs that didn't work for their specific tumor, wasting critical months while cancer progressed. The problem was measurable: roughly 90% of drugs that succeed in animal models fail in clinical trials, and even approved drugs only work for 20-30% of patients who receive them. Existing alternatives were limited to generic chemotherapy, trial-and-error drug selection, or expensive genomic sequencing that identified mutations but couldn't predict actual drug response. Early validation came when oncologists immediately recognized the value of patient-specific drug testing—hospitals and cancer centers began requesting the service before formal marketing. Additionally, the company's micro-tumor approach showed strong correlation with actual patient outcomes in early cases, demonstrating that their 3D cultures more accurately predicted clinical response than traditional 2D lab models. This clinical relevance from real patients validated that they'd identified a genuine, urgent problem.